These data indicated that XZP treatment inhibited the activation of bone cancer-related RANKL/RANK/OPG pathway and inflammation, leading to a reduction in the cancer-related bone destruction and alleviation of bone cancer pain in rats. This evidence concerns the gene TNFRSF11B and bone cancer.